Testing two medications together for advanced lung cancer

Plain-English translation of NCT07012031 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing whether two medications— and —work better when given together to treat advanced lung cancer. You would be eligible if your cancer has a specific genetic mutation (called KRAS G12C) and has progressed despite previous treatments. The study will measure whether this medication combination is safe and how well it works to shrink or control the cancer.

People with this type of lung cancer often run out of treatment options after their first few therapies stop working. Researchers believe that combining these two medications might help patients whose cancer no longer responds to standard treatments, offering a new hope for people with limited options.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation
your cancer has already been treated with a KRAS inhibitor, chemotherapy, and an immune checkpoint inhibitor (in any order)
your cancer has progressed or stopped responding to your most recent treatment
you are 18 years or older
you have measurable disease that can be tracked on imaging scans
your overall health status allows you to receive cancer treatment (ECOG performance status of 2 or better)

You likely don't qualify if…

you are under 18 years old
you do not have documented evidence of your KRAS G12C mutation from tumor tissue or blood testing
you lack medical records showing your prior treatments with KRAS inhibitors and other therapies
you do not have HER2 testing results or ERBB2 mutation status available from your tumor
your blood cell counts are too low (hemoglobin below 9, white blood cells below 3,000, or neutrophils below 1,500)

What participation looks like

You would receive one medication as an intravenous infusion (through an IV) once every three weeks and take the other medication as a daily oral pill for 21 days, then repeat this cycle. Throughout the study, you would have regular blood draws, imaging scans (CT or MRI), heart function tests, and a tumor biopsy at the start. If your cancer has spread to your brain, you would also have regular brain MRI scans. The study team will closely monitor you for side effects and track how well the treatment is working.

AI-generated summary from trial data · Aug 4, 2026 · Not medical advice

Testing two medications together for advanced lung cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(9 sites)